Reviewer’s report
Title:  Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic
colorectal cancer：a study from Guangxi Zhuang
Version: 1 Date: 29 Feb 2020
Reviewer: Li Yongqiang
Reviewer's report:
The paper presents an Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy
in metastatic colorectal cancer from Guangxi Zhuang,but the paper needs some improvement. My
detailed comments are as follows
1.Please arouse the enthusiasm in the first two sentences of the abstract 
2. Please insert the word " ECOG" between "a" and "PS" in the milddle sentence of  the methods about
patient selection 
3. Please correct the  formats errors about UGT1A1 in full text,Italics are recommended
4. Please replace all " X2 or X2" with All " χ2 ". 
5.Please correct all "P " with All  "p "
6.Please describe the total cycles of chemotherapy in the Chemotherapy regimen 
7.  Please delete "d " in the last sentence of response and toxicity evaluation
8.  Please describe the time of Median follow-up  and Lost visit rate in  the Response and toxicity
evaluation
9. Please lists the referenc  in  the Response and toxicity evaluation about   RECIST  guidelines
(version 1.1)  and NCI-CTC (version 3.0)
10  Please describe the day of each drug in the Chemotherapy regimen , For exmaple :"d1"
11. Please describe culation  method  of"Allele frequency"in Endpoints and Statistical analysis
12. Please replace all "- " with All "~ "between  the percentag ,for exmaple:  replace all "10 -15% " with
All "10 ~15% "
13 .Please Check all references,for exmaple:
2.Jakobsen A, Andersen F, Fischer A, et al: Neoadjuvant chemotherapy in locally advanced colon
cancer. A phase II trial. Acta Oncol,  54: 1747-1753, 2015.
3.Huo YR, Huang Y , Liauw W, Zhao J and Morris DL: Prognostic Value of Carcinoembryonic
Antigen  (CEA),  AFP,  CA19-9  and  CA125  for  Patients  with  Colorectal  Cancer  with  Peritoneal
Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. Anticancer Res
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional
statistical review?
If  an  additional  statistical  review  is  recommended,  please  specify  what  aspects  require  further
assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If
your reply is yes to any, please give details below.
I declare that I have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included on my
report to the authors and, if the manuscript is accepted for publication, my named report including any 
attachments I upload will be posted on the website along with the authors' responses. I agree for my 
report to be made available under an Open Access Creative Commons CC-BY license 
(http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments which I do not wish to 
be included in my named report can be included as confidential comments to the editors, which will not
be published.
I agree to the open peer review policy of the journal
Reviewer’s report
Title:  Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic
colorectal cancer：a study from Guangxi Zhuang
Version: 1 Date: 29 Feb 2020
Reviewer: Li Yongqiang
Reviewer's report:
The paper presents an Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy
in metastatic colorectal cancer from Guangxi Zhuang,but the paper needs some improvement. My
detailed comments are as follows
1.Please arouse the enthusiasm in the first two sentences of the abstract 
2. Please insert the word " ECOG" between "a" and "PS" in the milddle sentence of  the methods about
patient selection 
3. Please correct the  formats errors about UGT1A1 in full text,Italics are recommended
4. Please replace all " X2 or X2" with All " χ2 ". 
5.Please correct all "P " with All  "p "
6.Please describe the total cycles of chemotherapy in the Chemotherapy regimen 
7.  Please delete "d " in the last sentence of response and toxicity evaluation
8.  Please describe the time of Median follow-up  and Lost visit rate in  the Response and toxicity
evaluation
9. Please lists the referenc  in  the Response and toxicity evaluation about   RECIST  guidelines
(version 1.1)  and NCI-CTC (version 3.0)
10  Please describe the day of each drug in the Chemotherapy regimen , For exmaple :"d1"
11. Please describe culation  method  of"Allele frequency"in Endpoints and Statistical analysis
12. Please replace all "- " with All "~ "between  the percentag ,for exmaple:  replace all "10 -15% " with
All "10 ~15% "
13 .Please Check all references,for exmaple:
2.Jakobsen A, Andersen F, Fischer A, et al: Neoadjuvant chemotherapy in locally advanced colon
cancer. A phase II trial. Acta Oncol,  54: 1747-1753, 2015.
3.Huo YR, Huang Y , Liauw W, Zhao J and Morris DL: Prognostic Value of Carcinoembryonic
Antigen  (CEA),  AFP,  CA19-9  and  CA125  for  Patients  with  Colorectal  Cancer  with  Peritoneal
Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. Anticancer Res
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional
statistical review?
If  an  additional  statistical  review  is  recommended,  please  specify  what  aspects  require  further
assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If
your reply is yes to any, please give details below.
I declare that I have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included on my
report to the authors and, if the manuscript is accepted for publication, my named report including any 
attachments I upload will be posted on the website along with the authors' responses. I agree for my 
report to be made available under an Open Access Creative Commons CC-BY license 
(http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments which I do not wish to 
be included in my named report can be included as confidential comments to the editors, which will not
be published.
I agree to the open peer review policy of the journal
Please review this paper.
user
Reviewer’s report
Title:  Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic
colorectal cancer：a study from Guangxi Zhuang
Version: 1 Date: 29 Feb 2020
Reviewer: Li Yongqiang
Reviewer's report:
The paper presents an Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy
in metastatic colorectal cancer from Guangxi Zhuang,but the paper needs some improvement. My
detailed comments are as follows
1.Please arouse the enthusiasm in the first two sentences of the abstract 
2. Please insert the word " ECOG" between "a" and "PS" in the milddle sentence of  the methods about
patient selection 
3. Please correct the  formats errors about UGT1A1 in full text,Italics are recommended
4. Please replace all " X2 or X2" with All " χ2 ". 
5.Please correct all "P " with All  "p "
6.Please describe the total cycles of chemotherapy in the Chemotherapy regimen 
7.  Please delete "d " in the last sentence of response and toxicity evaluation
8.  Please describe the time of Median follow-up  and Lost visit rate in  the Response and toxicity
evaluation
9. Please lists the referenc  in  the Response and toxicity evaluation about   RECIST  guidelines
(version 1.1)  and NCI-CTC (version 3.0)
10  Please describe the day of each drug in the Chemotherapy regimen , For exmaple :"d1"
11. Please describe culation  method  of"Allele frequency"in Endpoints and Statistical analysis
12. Please replace all "- " with All "~ "between  the percentag ,for exmaple:  replace all "10 -15% " with
All "10 ~15% "
13 .Please Check all references,for exmaple:
2.Jakobsen A, Andersen F, Fischer A, et al: Neoadjuvant chemotherapy in locally advanced colon
cancer. A phase II trial. Acta Oncol,  54: 1747-1753, 2015.
3.Huo YR, Huang Y , Liauw W, Zhao J and Morris DL: Prognostic Value of Carcinoembryonic
Antigen  (CEA),  AFP,  CA19-9  and  CA125  for  Patients  with  Colorectal  Cancer  with  Peritoneal
Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. Anticancer Res
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional
statistical review?
If  an  additional  statistical  review  is  recommended,  please  specify  what  aspects  require  further
assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If
your reply is yes to any, please give details below.
I declare that I have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included on my
report to the authors and, if the manuscript is accepted for publication, my named report including any 
attachments I upload will be posted on the website along with the authors' responses. I agree for my 
report to be made available under an Open Access Creative Commons CC-BY license 
(http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments which I do not wish to 
be included in my named report can be included as confidential comments to the editors, which will not
be published.
I agree to the open peer review policy of the journal
assistant